Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. [electronic resource]
Producer: 20070328Description: 63-72 p. digitalISSN:- 0007-1048
- Anti-Infective Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Chi-Square Distribution
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Leukopenia
- Male
- Middle Aged
- Multivariate Analysis
- Remission Induction
- Respiratory Tract Infections -- drug therapy
- Risk Factors
- Survival Rate
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.